Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

(2015) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies

(2015) Alexander M.M. Eggermont et al.   SEMINARS IN ONCOLOGY

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

(2014) D. Schadendorf et al.   ANNALS OF ONCOLOGY

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

(2014) J.-J. Grob et al.   ANNALS OF ONCOLOGY

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

(2012) Dennis A Revicki et al.   Health and Quality of Life Outcomes

Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights

(2011) Robert L. Askew et al.   VALUE IN HEALTH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER